Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.55 CHF | -1.04% | -3.65% | -3.26% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Mar. 27 | Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.26% | 97.65M | |
+11.94% | 9.18B | |
-16.33% | 4.79B | |
+6.40% | 3.97B | |
+26.98% | 3.98B | |
+27.26% | 2.56B | |
-26.55% | 2.29B | |
-25.02% | 2.23B | |
+5.82% | 1.92B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SANN Stock
- News Santhera Pharmaceuticals Holding AG
- Santhera Pharmaceuticals : Accepts $43 Million in Conversion Offer For Bonds Due 2022, Extends Offer